» Articles » PMID: 32190070

Combined Interstitial and Surface High-dose-rate Brachytherapy Treatment of Squamous Cell Carcinoma of the Hand

Overview
Date 2020 Mar 20
PMID 32190070
Citations 2
Authors
Affiliations
Soon will be listed here.
Abstract

Purpose: We present a case report of treatment using interstitial and surface high-dose-rate (HDR) brachytherapy for cutaneous squamous cell carcinoma (SCC) involving the interspace of the third and fourth digits. The patient refused two-ray amputation and the lesion was not amenable for external beam radiation therapy (EBRT). This is the first report detailing combined interstitial and surface HDR brachytherapy for a hand SCC.

Material And Methods: The patient received 4050 cGy in 9 fractions, twice daily using 6 interstitial catheters and 8 Freiburg flap catheters. The clinical target was defined by MRI and ultrasound as a dorsal mass to the interspace between the heads of the third and fourth metacarpals measuring approximately 7 mm transverse × 5 mm volar-dorsal × 16 mm proximal-distal.

Results: The treatment resulted in radiographic and clinical tumor control. The patient retained functional use of her hand. However, there were both acute and late treatment-related side effects. Acutely, inpatient admission for pain control with a nerve block was needed. Long-term toxicity was notable for grade 2 skin necrosis treated with hyperbaric oxygen.

Conclusions: The first interstitial and surface HDR brachytherapy for cutaneous squamous cell carcinoma of a finger interspace for hand function preservation is presented. The initial experience revealed that brachytherapy was tolerated but with notable acute and late side effects. Treatment did result in tumor shrinkage with organ preservation and function of two rays. A larger cohort of patients will be required for additional conclusions related to long-term clinical benefits in patients who refuse ray amputation.

Citing Articles

Freiburg flap used as vaginal applicator with/without free-hand interstitial needles in three-dimensional high-dose-rate brachytherapy for vaginal stump recurrence of cervical cancer.

He M, Zhao H, Zhang Y, Zhang N, Zhao Z, Cheng G J Contemp Brachytherapy. 2024; 16(5):344-351.

PMID: 39719957 PMC: 11664794. DOI: 10.5114/jcb.2024.144531.


Advanced or Metastatic Cutaneous Squamous Cell Carcinoma: The Current and Future Role of Radiation Therapy in the Era of Immunotherapy.

Ferini G, Palmisciano P, Forte S, Viola A, Martorana E, Parisi S Cancers (Basel). 2022; 14(8).

PMID: 35454779 PMC: 9032290. DOI: 10.3390/cancers14081871.

References
1.
Conill C, Sanchez-Reyes A, Molla M, Vilalta A . Brachytherapy with 192Ir as treatment of carcinoma of the tarsal structure of the eyelid. Int J Radiat Oncol Biol Phys. 2004; 59(5):1326-9. DOI: 10.1016/j.ijrobp.2004.01.048. View

2.
Alam M, Nanda S, Mittal B, Kim N, Yoo S . The use of brachytherapy in the treatment of nonmelanoma skin cancer: a review. J Am Acad Dermatol. 2011; 65(2):377-388. DOI: 10.1016/j.jaad.2010.03.027. View

3.
Locke J, Karimpour S, Young G, Lockett M, Perez C . Radiotherapy for epithelial skin cancer. Int J Radiat Oncol Biol Phys. 2001; 51(3):748-55. DOI: 10.1016/s0360-3016(01)01656-x. View

4.
Brantsch K, Meisner C, Schonfisch B, Trilling B, Wehner-Caroli J, Rocken M . Analysis of risk factors determining prognosis of cutaneous squamous-cell carcinoma: a prospective study. Lancet Oncol. 2008; 9(8):713-20. DOI: 10.1016/S1470-2045(08)70178-5. View

5.
Murakami N, Ueno T, Yatsuoka W, Okamoto H, Tselis N, Masui K . Dose coverage comparison between "interstitial catheter-only" and "hybrid intracavitary-interstitial brachytherapy" for early stage squamous cell carcinoma of the buccal mucosa. J Contemp Brachytherapy. 2018; 10(5):486-491. PMC: 6251447. DOI: 10.5114/jcb.2018.79471. View